NCT04849260View on ClinicalTrials.gov

Phase Ib/II Clinical Study of Pexa-Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Combined With Recombinant Whole Human Anti-PD-L1 Monoclonal Antibody (ZKAB001) in Metastatic Melanoma

PHASE1/PHASE2UnknownINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 26, 2021

Primary Completion Date

May 31, 2022

Study Completion Date

May 31, 2023

Conditions

Local Progression or Metastatic Melanoma With Failed First-line Treatment

Interventions

BIOLOGICAL

Pexa-Vec combined with ZKAB001

"1. Intratumoral injection of low dose Pexa-Vec (3×10\^8pfu) combined with intravenous of ZKAB001 (5mg/kg), every 2 weeks as one cycle.~2. Intratumoral injection of high dose Pexa-Vec (1×10\^9pfu) combined with intravenous of ZKAB001 (5mg/kg), every 2 weeks as one cycle."

BIOLOGICAL

ZKAB001 monotherapy

Trial Locations (1)

Unknown

RECRUITING

Beijing Cancer Hospital, Beijing